Equities Analysts Offer Predictions for MNPR Q3 Earnings

Posted by George Bondi on Aug 18th, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Investment analysts at HC Wainwright cut their Q3 2026 EPS estimates for Monopar Therapeutics in a research report issued on Thursday, August 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.90) per share for the quarter, down from their prior estimate of ($0.79). HC Wainwright has a “Buy” rating and a $125.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.96) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($3.07) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at $0.87 EPS.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02.

MNPR has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $109.00 to $119.00 in a report on Thursday. BTIG Research increased their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

View Our Latest Research Report on Monopar Therapeutics

Monopar Therapeutics Trading Up 3.1%

Shares of MNPR stock opened at $116.49 on Monday. The company has a market capitalization of $781.65 million, a P/E ratio of -53.68 and a beta of 1.47. The business’s 50 day moving average is $97.23 and its two-hundred day moving average is $71.85. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics during the 3rd quarter worth $28,000. BNP Paribas Financial Markets grew its stake in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Sei Investments Co. increased its holdings in Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after acquiring an additional 656 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics during the fourth quarter worth about $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.